Technology

   A growing worry in medicine is bugs’ increasing resistance to antibiotics. At AstraZeneca’s research centre near Boston, scientists toil to find new weapons. Machines screen thousands of drugs each year, robotic arms nimbly handling...

DuPont last week opened a new five-story, 220,000 square foot office building at its Chestnut Run facility – incorporating sustainability into the building design and using more than 20 DuPont innovations. The building is...

 SDIX, a Glasgow, Del. provider of biotechnology-based products and services reported a loss for the quarter and a partnership with a drug company. Revenue for the first quarter of 2012 was $5.6 million, down...

DuPont,  on May 1,  took  full ownership of St. Louis-based soy-based ingredients  joint venture  Solae. DuPont previously owned 72 percent  of the joint venture while grain merchant  Bunge owned the  remainder. Published reports indicate...

Most businesspeople in Delaware know little about Incyte. The pharmaceutical development company, based in DuPont research space at the Experimental Station has quietly built a portfolio of promising drugs while posting big losses. Earlier in the...

Drug developer Incyte Corp. is reporting revenue from a new product on the market, although the company's loss widened in the first quarter, due to higher research and other expenses as its pharmaceuticals moved...

  AstraZeneca headquarters in London. AstraZeneca is betting on the success of a promising drug used to treat gout in  its merger deal for Ardea Biosciences, Inc. AstraZeneca will acquire Ardea, a San Diego-based biotechnology company...

AstraZeneca and Bristol-Myers Squibb Company reported a committee for a European Union agency has recommended the approval of FORXIGA tablets for the treatment of type 2 diabetes. The drug is used in additon to diet...

The Delaware Biotechnology Institute and the Delaware Economic Development Office announced eight research projects through the recently launched Delaware Bioscience Center for Advanced Technology (Bioscience CAT). CAT grants link researchers from Delaware academic and...

Newark-based IBIO announced that its iBioLaunch plant-based technology for the production of a copy of palivizumab, an antibody that fights a condition that strikes infants. Palivizumab is used to cut hospitalizations, but its high cost...